Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New beta-blocker to offer hope to heart and lung sufferers

29.08.2008
Researchers at The University of Nottingham have been awarded £2.8 million by the Wellcome Trust to develop a new drug that could ease the suffering of hundreds of thousands of heart disease patients who are unable to take beta-blockers.

In the UK, 2.6 million people suffer from heart disease and most are able to have their symptoms effectively managed with the prescription of beta-blocker drugs which stop adrenaline from making the heart work too hard.

However, a major side effect of beta-blockers is that they make the symptoms of asthma and other breathing problems worse, so that around 300,000 patients in the UK who also suffer from respiratory conditions are prevented from taking them.

Now, a team of scientists from the University’s Schools of Biomedical Sciences and Pharmacy will use the Wellcome Trust’s funding, made under the Seeding Drug Discovery initiative, to conduct a three-year study to develop a modified type of beta-blocker that will treat heart disease and angina without exacerbating any underlying respiratory problems..

If successful, the new drug could become the general medicine of choice for all heart patients because its targeted action will lead to a significant reduction in overall side effects.

Even the best currently available beta-blockers are poor at discriminating between the heart and lungs, causing the muscles in the lungs to tighten and making breathing more difficult in some patients who have a pre-existing lung complaint.

In patients suffering from asthma, in which environmental factors cause muscle contractions leading to a narrowing of the airway, taking these medicines can trigger an attack or, even if tolerated enough to be taken regularly, can stop other asthma drugs from working.

Doctors are also extremely wary in prescribing beta-blockers for patients suffering from heart disease and chronic obstructive pulmonary disease (COPD), a progressive condition which causes the destruction of lung tissue and increased mucus production, because any reduction in respiratory function that may be caused by the drugs could have a major impact on symptoms.

The Nottingham scientists have already developed a molecule that is much more effective at discriminating between the heart and lungs than current drugs. The funding will allow them to carry out further studies to improve the molecule to ensure that it is able to target the heart cells more effectively — therefore directing the therapeutic effect only to the heart and not the lungs. The aim is that the resulting drug will be long-lasting and could be taken orally.

Leading the research, Dr Jill Baker from the School of Biomedical Sciences said: “Once developed, this molecule will cause much less wheezing and shortness of breath and should be able to be given safely to the hundreds of thousands of patients with both heart and lung diseases. Furthermore, because it will have so few side effects, it has the potential to become the beta-blocker of choice for all heart patients.”

Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust, said: “We know that beta-blockers save lives in patients with heart disease, so making them safe for those unlucky enough to have a respiratory disorder as well is a clinical imperative. I applaud Jill Baker for questioning why beta-blockers should remain contraindicated for so many of her patients, and being stirred to correct this with an incisive programme of work. In the best traditions of medical research, this endeavour was born out of a problem encountered at the sharp end of clinical practice.”

Emma Thorne | alfa
Further information:
http://www.nottingham.ac.uk
http://www.wellcome.ac.uk

More articles from Life Sciences:

nachricht Making fuel out of thick air
08.12.2017 | DOE/Argonne National Laboratory

nachricht ‘Spying’ on the hidden geometry of complex networks through machine intelligence
08.12.2017 | Technische Universität Dresden

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

Im Focus: Successful Mechanical Testing of Nanowires

With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong

Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...

Im Focus: Virtual Reality for Bacteria

An interdisciplinary group of researchers interfaced individual bacteria with a computer to build a hybrid bio-digital circuit - Study published in Nature Communications

Scientists at the Institute of Science and Technology Austria (IST Austria) have managed to control the behavior of individual bacteria by connecting them to a...

Im Focus: A space-time sensor for light-matter interactions

Physicists in the Laboratory for Attosecond Physics (run jointly by LMU Munich and the Max Planck Institute for Quantum Optics) have developed an attosecond electron microscope that allows them to visualize the dispersion of light in time and space, and observe the motions of electrons in atoms.

The most basic of all physical interactions in nature is that between light and matter. This interaction takes place in attosecond times (i.e. billionths of a...

Im Focus: A transistor of graphene nanoribbons

Transistors based on carbon nanostructures: what sounds like a futuristic dream could be reality in just a few years' time. An international research team working with Empa has now succeeded in producing nanotransistors from graphene ribbons that are only a few atoms wide, as reported in the current issue of the trade journal "Nature Communications."

Graphene ribbons that are only a few atoms wide, so-called graphene nanoribbons, have special electrical properties that make them promising candidates for the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

Blockchain is becoming more important in the energy market

05.12.2017 | Event News

 
Latest News

Making fuel out of thick air

08.12.2017 | Life Sciences

Rules for superconductivity mirrored in 'excitonic insulator'

08.12.2017 | Information Technology

Smartphone case offers blood glucose monitoring on the go

08.12.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>